Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
SUO 2024: Heterogeneity of Intermediate Risk NMIBC
Intermediate risk NMI - Activity Eight: Optimal Surveillance for Follow ...
SUO 2025: Trial Updates in Intermediate Risk NMIBC
SUO 2025: Intermediate Risk NMIBC: Risk Stratification
AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges
Intermediate risk | British Association of Paediatric Surgeons
Episode 2 Video: Identifying Patients with Intermediate Risk in NMIBC
Intermediate Risk Pulmonary Embolism Risk Stratification & Management ...
Trial Design Considerations for Intermediate Risk Non Muscle-Invasive ...
Characteristics of patients with low (G1) and intermediate (G2) risk ...
(PDF) Managing Acute Intermediate Risk Pulmonary Thromboembolism in a ...
Impact of Pathologic Re-Review on Grade, Clinical Stage, and Risk ...
EAU 2023: Healthy Patient with Very High Risk NMIBC: What Is Best ...
AUA 2025: Patient with High Risk NMIBC: Balancing BCG with New and ...
Risk Stratification and Management of Intermediate-Risk Acute Pulmonary ...
What Are the Different Risk Stratification Levels in NMIBC? | CG Oncology
UROWebinar: NMIBC from intermediate to high risk: Current landscape and ...
Eau Nmibc Risk Calculator : Intermediate-risk Non – IKCA
SUO 2024: Primary Chemoablation of Recurrent Low-Grade Intermediate ...
FDA Approves Zusduri (Mitomycin) for Recurrent Low-Grade Intermediate ...
Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate ...
AUA 2018: Application of AUA Risk Stratification for NMIBC: Long-term ...
EAU NMIBC RISK CALCULATOR.pptx
AUA 2025: PIVOT-006: A Phase 3, Randomized Study of Adjuvant ...
Ashish Kamat: Updated Recommendations for Intermediate-Risk NMIBC ...
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus ...
Recommendations for Managing Intermediate-Risk NMIBC | www ...
Bladder Cancer: Non-Muscle Invasive Guideline - American Urological ...
ASCO GU 2025: ResQ132A: Phase 2 Trial of Intravesical Gemcitabine Plus ...
Proposed substratification of intermediate-risk non-muscle-invasive ...
Next Generation Urothelial Carcinoma - Grand Rounds in Urology
NMIBC - URORESIDENT.COM
PinPointcases - Challenges in high-risk NMIBC
Cretostimogene Grenadenorepvec: At the CORE and Forming BONDs in High ...
PinPointcases - Follow-up surveillance regimes to consider for (very ...
NMIBC
-Risk stratification of NMIBC in clinical practice guidelines ...
Markov model of health states during surveillance for NMIBC. NED no ...
Non muscle invasive bladder cancer treatment - WCRJ
ASCO GU 2024: Urine-Based Testing for Patient Selection and Genomic ...
Clinical validation of the Intermediate-risk NMIBC Scoring System and ...
EAU 2025: A Real-World Evidence Study Evaluating the Prevalence of FGFR ...
EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb
EAU 2025: Low-risk Recurrent NMIBC in the Elderly Patient – Fulguration ...
Improving Knowledge of Surveillance Practices in Non-muscle Invasive ...
Urothelial Cancer, Immunotherapy: SITC
AUA 2024: Role of Urinary Markers in Surveillance of NMIBC Patients
New Approaches for Bladder Preservation in NMIBC | RRU
SIU 2018: Early Cystectomy for High-Risk NMIBC: Is it Appropriate?
(PDF) Alternating Cystoscopy with Bladder EpiCheck ® in the ...
SUO 2024: Home Instillation of UGN-102 for Primary Chemoablation of ...
SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized ...
Ashish Kamat: IBCG scoring system and substratification model for IR ...
Focus on Intermediate-Risk Acute Pulmonary Embolism. Is the Combination ...
WSAUA 2025: Impact of Tumor Burden or Focality on Duration of Response ...
Towards Defining Follow-up Strategies for Patients with Primary ...
UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade ...
MoonRISe-1: A Targeted Approach to Intermediate-Risk NMIBC | Targeted ...
ESMO 2024: Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically ...
Guideline definitions of low-, intermediate- and high-risk ...
Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer ...
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
ASCO GU 2025: ABLE-32: A Randomized, Controlled, Phase 3b Clinical ...
Overview of Management of Intermediate- and High-Risk Pulmonary ...
Novel Approaches and Recent Trial Updates in Intermediate-risk NMIBC
FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC
PPT - SYNCOPE PowerPoint Presentation, free download - ID:4997370
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade ...
Phase 3 Randomized Controlled Trial of Chemohyperthermia vs BCG in ...
Recent advancements in the diagnosis and treatment of non‐muscle ...
FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade ...
UGN-102 Yields CRs in 4 out of 5 Patients With Intermediate-Risk NMIBC ...
UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With ...
SUO 2025: RECURxNCE-BCa – An Artificial Intelligence-Based Tool to ...
Table 1 from Alternating Cystoscopy with Bladder EpiCheck® in the ...
Experimental and New Approaches For Bladder Preservation in ...
WSAUA 2025: PIVOT-006: Ongoing Phase 3, Randomized Study of Adjuvant ...
(PDF) Intermediate-Risk Pulmonary Embolism: A Review of Contemporary ...
Management of carcinomas of urinary bladder | PPTX
UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low ...
PPT - Managing Intermediate-Risk Patients: A Comprehensive Approach ...
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC ...
Alternating cystoscopy with a urinary marker for the surveillance of ...
Table 1 from Experimental and New Approaches for Bladder Preservation ...
